DPLIFE PRIME

 

DPLIFE-PRIME

 

Composition:

Each Enteric-coated Tablet contains:

Doxylamine succinate       20 mg

Pyridoxal 5’-Phosphate    10 mg

L-Methylfolate calcium     1 mg

Mecobalamin IP                 1500 mcg

 

Pharmacodynamic

Doxylamine succinate:

Doxylamine succinate is classified as an antihistamine

Doxylamine Succinate effectively blocks the Chemo Receptor Trigger Zone thereby inhibiting the binding of neurotransmitters and controls Nausea

Pyridoxal 5’-Phosphate 

Bioactive form of Pyridoxine Hydrochloride (Vitamin B6). Has been known to possess antiemetic effects though the mechanism of action is not well know. Well tested for efficacy and safety in NVP, alone and in combination with Doxylamine succinate

L-MethylFolate (LMF)

Bioactive form of Folic acid

Significantly lowers risk of NTDs & Cleft palate

Significantly lowers the risk of Hyperhomocysteinemia and the associated risks & complications in Pregnancy

 MECOBALAMIN

Bioactive form of Vitamin B12

Reduces risks of Neural Tube defects alongwith Folate

Lowers the risk of  Hyperhomocysteinemia and associated Pregnancy Complications

 

Indication:

For the Prevention & Treatment of Nausea & Vomiting of Pregnancy

To reduce the Risk of Neural Tube Defects

To reduce the risk of Hyperhomocysteinemia & its complications in pregnancy

Dosage:

1 Tablet Daily or as Directed by the Physician

Storage:

Store protected from light & moisture, at a temperature not exceeding 25°C

Pharmacokinetic:

Absorbed mainly from the jejunum (small intestine). Hence enteric-coated tablets used. Peak plasma concentrations, after using delayed-release preparations is around 4-7 hours (Hence the drug is given at bedtime). Doxylamine is metabolised in the liver. Metabolites are excreted through kidneys